Patents by Inventor Chan-Hwa Kuo

Chan-Hwa Kuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxadiazole benzenesulfonamides as selective .beta..sub.3 Agonist for the treatment of Diabetes and Obesity
    Patent number: 6034106
    Abstract: Oxadiazole substituted benzenesulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: March 7, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Michael H. Fisher, Danqing Dennis Feng, Chan-Hwa Kuo, Gui-Bai Liang, Elizabeth M. Naylor, Ann E. Weber
  • Cholesterol lowering compounds
    Patent number: 5506262
    Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthetase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.
    Type: Grant
    Filed: November 10, 1993
    Date of Patent: April 9, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Robert M. Burk, William H. Parsons, John J. Acton, III, Gregory D. Berger, Tesfaye Biftu, Robert L. Bugianesi, Yuan-Ching P. Chiang, Claude Dufresne, Narindar N. Girotra, Robert W. Marquis, Jr., Chan-Hwa Kuo, Sandra P. Plevyak, Mitree M. Ponpipom, Lori L. Whiting, James D. Bergstrom, Conrad Santini
  • Cholesterol lowering compounds
    Patent number: 5326783
    Abstract: This invention is directed to compounds of formula (I) which are novel C3- or C5-acyl sulfonamide, carboxamic acid or tetrazolyl analogs of the Zaragozic acids. These compounds inhibit the enzyme squalene synthase and are useful as cholesterol lowering agents.
    Type: Grant
    Filed: January 19, 1993
    Date of Patent: July 5, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Tesfaye Biftu, Chan-Hwa Kuo, Conrad Santini
  • Process for 4a'(R),5'-dihydromevinolin
    Patent number: 4490546
    Abstract: Mevinolin is converted to its 4a',5'-dihydro derivative by a route involving protection of the 3',4'-double bond followed by reduction of the 4a',5'-double bond followed by deprotection of the 3',4'-positions.
    Type: Grant
    Filed: June 20, 1983
    Date of Patent: December 25, 1984
    Assignee: Merck & Co., Inc.
    Inventor: Chan-Hwa Kuo
  • Hypocholesterolemic hydrogenation products and process of preparation
    Patent number: 4351844
    Abstract: Hydrogenation of the natural fermentation product, mevinolin, MK-803, results in the production of dihydro- and tetra-hydro derivatives and hydrogenation of the naturally occurring dihydromevinolin results in the formation of a tetrahydro derivative. These several products with the exception of cis-(4.alpha..beta., 8.alpha..beta.-)-tetrahydromevinolin are potent inhibitors of cholesterol biosynthesis.
    Type: Grant
    Filed: December 1, 1980
    Date of Patent: September 28, 1982
    Assignee: Merck & Co., Inc.
    Inventors: Arthur A. Patchett, Chan-Hwa Kuo
  • Prostaglandin E.sub.1 intermediate 3-carboxymethyl-4-methyl-2-1-carboxy-7-(loweralkoxy or aralkoxycarbonyl)-heptyl]-4-hydroxybutyric acid, .gamma.-lactone, and processes of their preparation
    Patent number: 3965120
    Abstract: Disclosed is a novel stereospecific synthesis of Prostaglandin E.sub.1.
    Type: Grant
    Filed: February 11, 1975
    Date of Patent: June 22, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Chan-Hwa Kuo, David Taub, Norman L. Wendler
  • Prostaglandin E.sub.1 intermediate 6.alpha.-carboxy-5.alpha.(1-hydroxyethyl)-2-cyclohexene-1-heptanoic acid,.gamma.-lactone, and lower alkyl or aralkyl esters thereof
    Patent number: 3939182
    Abstract: 6 .alpha.-Carboxy-5.alpha. (1-hydroxyethyl)-2-cyclohexene-1-heptanoic acid, .gamma. - lactone, and lower alkyl and aralkyl esters thereof, are useful intermediates for the production of Prostaglandin E.sub.1.
    Type: Grant
    Filed: February 11, 1975
    Date of Patent: February 17, 1976
    Assignee: Merck & Co., Inc.
    Inventors: Chan-Hwa Kuo, David Taub, Norman L. Wendler